Proteomics International Laboratories (PIQ) Q1 2026 TU earnings summary

Executive summary

• Achieved ISO 15189 clinical certification for Australian laboratory operations, supporting commercialisation of precision diagnostic tests.

• Launched PromarkerD (diabetic kidney disease) and PromarkerEso (esophageal cancer) tests nationally in Australia, with first sales recorded for both.

• Expanded PromarkerEndo (endometriosis) collaboration and advanced OxiDx (oxidative stress) test development.

• Founder and Managing Director to retire in February 2026; CEO search underway.

Financial highlights

• Cash receipts from customers for the quarter were $1.86 million, including a non-recurring $1.71 million from a public-private partnership.

• Net operating cash outflow for the quarter was $0.8 million, a significant improvement from the previous quarter's $3.2 million outflow.

• Cash reserves at 30 September 2025 stood at $10.0 million, with an expected $2 million R&D tax rebate in 1H FY26.

Outlook and guidance

• PromarkerEndo commercial launch targeted for H2 CY25 in Australia, with international expansion to follow.

• OxiDx test launch planned for H2 CY25 in Australia, with US expansion via reference laboratory.

• Estimated 13 quarters of funding available, excluding the anticipated R&D tax rebate.